Log In
BCIQ
Print this Print this
 

Redectane, 124-Iodine-girentuximab (CA9-SCAN)

Also known as: WX-G250RIT

  Manage Alerts
Collapse Summary General Information
Company Wilex AG
DescriptionRadiolabeled WX-G250 antibody
Molecular Target Carbonic anhydrase IX (CAIX)
Mechanism of ActionDiagnostic; Radiolabelled antibody
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentPhase III
Standard IndicationCancer, Diagnostic
Indication DetailsDiagnose clear cell renal cell carcinoma (ccRCC)
Regulatory Designation U.S. - Special Protocol Assessment (Diagnose clear cell renal cell carcinoma (ccRCC))
PartnerIon Beam Applications S.A.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$21.1M

0

$14.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/12/2009

$21.1M

0

$14.0M

Get a free BioCentury trial today